Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction
Completed · Phase 2
Conditions studied: Congestive Heart Failure, Renal Insufficiency
In brief
The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.
Key facts
- Study ID
- NCT00119691
- Run by
- Brigham and Women's Hospital
- People needed
- 34
- Starts
- 2003-04-01
- Expected to finish
- 2005-11-01
- Last updated by the study team
- 2013-09-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Decompensated heart failure hospitalization with at least 1 symptom and 1 sign of elevated filling pressures
- Admission estimated creatinine clearance =< 50 cc/min.
You may not qualify if…
- Systolic blood pressure < 85 mm Hg
- Cardiogenic shock
- Volume depletion
- Myocardial infarction, unstable angina within last 30 days
- Significant valvular stenosis, hypertrophic/restrictive cardiomyopathy, or constrictive pericarditis
- Chronic hemodialysis
- Anticipated major procedure during hospitalization i.e. left heart catheterization, surgery, or transplantation
- Enrolled in another research protocol within last 30 days.
Where it is running
- Brigham and Women's Hospital — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.